MYO MYOMO, INC.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Wearable myoelectric-controlled upper limb orthoses for neuromuscular disorders and paralysis
• • New emphasis on upcoming MyoPro3 and MyoPal pediatric device to expand product lineup
• • Strategic shift toward broader direct billing and increased sales through O&P providers and international markets, including EU and Canada
• • Patient pipeline grows 10% to 1,528, backlog down 27% to 199 units, revenue up 26% in 2025 despite lower backlog
• • CMS reimbursement updated Jan 1, 2026 at approx. $68,800 for powered grasp (L8702 code), providing clearer payer framework

Risk Factors

• • CMS reclassification of MyoPro to brace benefit category effective January 1, 2024 enabling lump sum reimbursement around $34,970 to $68,800 per device
• • Medicare Advantage plans reduced MyoPro authorizations causing 2% revenue decline in 2025; 20% of product revenues from these plans in 2025
• • Reliance on Cogmedix as sole contract manufacturer for key subassemblies risks supply delays, regulatory compliance issues, and costly transfer of production
• • Social media algorithm changes in Q1 2025 impaired lead generation, increasing advertising cost per addition to patient pipeline
• • Loan and Security Agreement with Avenue in Nov 2025 secures $17.5 million funding with covenants requiring $2.5 million minimum cash and 75% of projected revenue

Management Discussion & Analysis

• • Revenue $40.9M in 2025, up 26% YoY from $32.6M driven by higher volume and ASP; direct billing $30.4M (74% of total, +20%), International $6.8M (+48%), U.S. O&P $2.9M (doubled), VA $0.8M (-31%)
• • Gross margin declined to 65.7% in 2025 from 71.2% in 2024, due to higher overhead capitalization changes and warranty expenses
• • Best performing segment: International with 48% growth to $6.8M; worst performing segment: VA with 31% decline to $0.8M
• • Cash used in operations $14.5M in 2025; capital expenditures approx. $3.3M including furniture, fixtures, and software; net proceeds $15.8M from Dec 2024 equity offering and $17.5M term loan facility raised in Nov 2025
• • 2026 outlook: focus on recurring revenues from MyoConnect referrals and O&P providers, reducing direct advertising costs, managing fixed expenses and improving gross margin through volume and cost reductions; risk from dependence on insurance reimbursement

What are the latest MYO SEC filings in 2026?

MYOMO, INC. (MYO) has filed a 10-K annual report on March 9, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did MYO file its most recent 10-K annual report?

MYOMO, INC. (MYO) filed its most recent 10-K annual report on March 9, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view MYO 10-Q quarterly reports?

MYOMO, INC. (MYO)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every MYO 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has MYO filed recently?

MYOMO, INC. (MYO)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find MYO insider trading activity (Form 4)?

SignalX aggregates every MYO Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does MYO file with the SEC?

MYOMO, INC. (MYO) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new MYO filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for MYOMO, INC. (MYO).

What is MYO's SEC CIK number?

MYOMO, INC. (MYO)'s SEC CIK (Central Index Key) number is 1369290. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1369290 to look up all MYO filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find MYO return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from MYOMO, INC. (MYO) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.